Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.

Author(s): Jason Whitt, Krishna C. Vallabhaneni, Patrice Penfornis, Radhika Pochampally.

Journal Name: Current Stem Cell Research & Therapy

Volume 11 , Issue 2 , 2016

Become EABM
Become Reviewer

Abstract:

Mesenchymal Stem/stromal cell (MSCs) transplantation procedures have been used since the 1960’s to treat leukemia and other diseases, but due to the risks involved only patients with life threatening illnesses were typically subjected to the transplantation procedure until the last decade. Recent advancements in transplantation techniques have made it more feasible to use it for non-life-threatening diseases. However, the potential uses for stem cells are still limited by their rarity, and, in the case of allogeneic transplants, graft-vs.-host complications. An evolving alternative to conventional stem cell therapies is induced pluripotent stem-cell derived mesenchymal stem/stromal cells (iPSC- MSCs), which have a multi-lineage potential comparable to conventionally acquired MSCs with the added benefit of being less immunoreactive. However there are still many hurdles left to be overcome before they can be used regularly for personalized therapies. This review will focus on recent advancements that have been made regarding the role MSCs play in tumor development and the potential uses iPSC-MSCs may have in future cancer treatment.

Keywords: Cancer, cell therapy, iPSCs, MSCs, precision medicine.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 2
Year: 2016
Page: [141 - 148]
Pages: 8
DOI: 10.2174/1574888X10666151001114321
Price: $58

Article Metrics

PDF: 39
HTML: 2